{"id":"W3212299214","doi":"10.1182/blood-2021-152561","title":"Efficacy and Safety Results from Ascembl, a Multicenter, Open-Label, Phase 3 Study of Asciminib, a First-in-Class STAMP Inhibitor, Vs Bosutinib in Patients with Chronic Myeloid Leukemia in Chronic Phase after ≥2 Prior Tyrosine Kinase Inhibitors: Update after 48 Weeks","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Bosutinib; Medicine; Discontinuation; Tolerability; Internal medicine; Adverse effect; Nilotinib; Imatinib mesylate; Imatinib; Myeloid leukemia; Gastroenterology; Oncology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003204172,0.001419466,0.001800667,0.0004231972,0.0005349885,0.001187059,0.0007071017,0.001584687,0.00355439],"category_scores_gemma":[0.001761486,0.0004866976,0.00249239,0.0004665404,0.0007857247,0.001063701,0.000317356,0.003513501,0.0007433586],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00103172,"about_ca_system_score_gemma":0.001028424,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006673005,"about_ca_topic_score_gemma":0.001491997,"domain_scores_codex":[0.999206,0.000397989,0.00005586273,0.0001248239,0.0001013919,0.0001140128],"domain_scores_gemma":[0.9982648,0.0003959805,0.0005481514,0.00009407281,0.0001527809,0.0005441898],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8770222,0.02122879,0.007368199,0.0008741112,0.00198731,0.0001286517,0.0001712689,0.002026154,0.01878501,0.0001691857,0.004757414,0.06548177],"study_design_scores_gemma":[0.6000306,0.3519605,0.03823589,0.00008428395,0.001395637,0.000316769,0.00005740347,0.001912817,0.002961262,0.0002446198,0.002741806,0.00005838056],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9849881,0.007295469,0.0006113689,0.0007076863,0.0001351214,0.001142365,0.002791185,0.0001099003,0.002218783],"genre_scores_gemma":[0.9902763,0.001760604,0.0007886076,0.0009814324,0.0002293382,0.0008477724,0.003692825,0.00002998835,0.001393059],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00355439,"threshold_uncertainty_score":0.01694548,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01260281943940314,"score_gpt":0.278387262362273,"score_spread":0.2657844429228698,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}